Loading stock data…
Erasca, Inc. (ERAS)
$18.29+2.28 (+14.24%)
After Hours$18.33+0.04 (+0.22%)· Last close Jun 29
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Erasca, Inc. in the Healthcare sector is trading at $18.29 with a market capitalization of $4.1B. Wall Street consensus targets $21.00 (10 analysts), implying a +14.8% move over the next 12 months. The stock is currently 25% below its 52-week high of $24.28, remaining 103.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +14.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$37.91M↓ | -$32.60M↓ | -$32.55M↓ | -$30.63M↑ | -$35.63M |
| Net Income | -$183.44M↓ | -$29.09M↑ | -$30.61M↑ | -$33.88M↓ | -$30.97M |
Peer Comparison
JNJUNHPFE
Fundamentals
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.10B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.68
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-70.39%
Volume
Today's trading volume
7.98M
Recent News
Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid Tumors
Verastem (VSTM) said late Tuesday that preliminary data from its ongoing Phase 1/2 TARGET-D 101 tria
Erasca (ERAS) Receives Encouraging Expert Feedback on ERAS-0015 Clinical Trials
Erasca Inc. (NASDAQ:ERAS) is one of the 10 best AI driven biotech stocks to invest in. As of the close of play on June 5, consensus sentiment for Erasca Inc. (NASDAQ:ERAS) was strongly bullish. Based on a 1-year target price of $21, the stock offers an upside potential of more than 75% at the current […]
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Tango Therapeutics rises 53% after early pancreatic cancer study data show strong response rates for vopimetostat combinations and support late-stage plans.
Erasca (ERAS) Is Down 13.4% After IP Challenge to ERAS-0015 Trade Secrets and Patents
Erasca recently faced a legal challenge from competitor Revolution Medicines over alleged trade secret misappropriation and patent infringement tied to its lead oncology candidate ERAS-0015, prompting a shareholder rights law firm to investigate whether investors were misled about the strength of its intellectual property position. This dispute strikes at the core of Erasca’s pan-RAS development story, as ERAS-0015 underpins both its pipeline focus and its emerging clinical and partnership...
Erasca Inc. (ERAS) Inspiring Confidence Through Commercial Collaborations
Erasca Inc. (NASDAQ:ERAS) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 11, Erasca Inc. (NASDAQ:ERAS) announced a supply agreement and a clinical trial partnership with Merck. The collaboration is aimed at facilitating the AURORAS-1 clinical proof-of-concept research. This research thoroughly assesses the exclusive pan-RAS molecular glue ERAS-0015 […]